User login
Diseases such as Clostridium difficile infection, inflammatory bowel disease, and liver cancer continue to cost billions and cause many thousands of deaths in the United States every year, investigators reported in the December issue of Gastroenterology.
“Gastrointestinal and liver diseases are a source of substantial burden and cost,” said Dr. Anne Peery and her associates at the University of North Carolina School of Medicine and the Gillings School of Public Health, both in Chapel Hill. The Affordable Care Act has extended health insurance to more than 16 million Americans, which is “expected to change the landscape of care for GI illnesses” and intensifies the need for their comprehensive study, the researchers added.
They analyzed health care visits, costs, and deaths from GI, pancreatic, and hepatic diseases for 2007 through 2012 by using surveillance data from the Centers for Disease Control and Prevention, the Agency for Healthcare Research and Quality, and the National Cancer Institute. Chronic hepatitis C virus infection was a leading disease burden, they found. Associated emergency department visits rose by 176% between 2006 and 2012, hospital admissions increased by 225% between 2003 and 2012, and in-hospital mortality approached 6%. These trends reflect the aging of baby boomers, who make up three-quarters of infected patients, the investigators noted. As a result, rates of new liver cancers also are rising, and end-stage liver disease is expected to keep increasing until 2030, they added (Gastroenterology. 2015 Aug 20. doi: 10.1053/j.gastro.2015.08.045). Aging boomers are increasingly seeking care for other age-related GI disorders, the investigators reported. Outpatient visits for hemorrhoids are rising, as are emergency department visits for constipation and lower-GI bleeding, and hospitalizations for acute diverticulitis and C. difficile infection. Gastrointestinal hemorrhage was the most common diagnosis at hospitalization, accounting for more than 500,000 discharges and costing almost $5 billion dollars in 2012 alone, the researchers said.
Despite better treatments, hospital admissions for Crohn’s disease and ulcerative colitis also rose from less than 60,000 in 1993 to about 100,000 in 2012, said Dr. Peery and her associates. “This is congruent with earlier trends using the National Hospital Discharge Survey. Emergency department visits [for inflammatory bowel disease] are also rising,” they added.
In contrast, cases and deaths from colorectal cancer continue to drop, partly because of intensified screening efforts, the investigators said. They called the trend “encouraging,” but noted that CRC still tops cancers of the pancreas, liver, and intrahepatic bile ducts as the leading GI cause of mortality in the United States. In 2012, more than 51,000 Americans died from CRC, and screening efforts captured only 58% of those between 50 and 75 years old. Boosting that percentage to 80% by 2018 http://nccrt.org/tools/80-percent-by-2018/ could prevent 280,000 CRC cases and 200,000 deaths within 20 years, Dr. Peery and her associates noted.
The National Institutes of Health helped fund the work. The investigators reported having no conflicts of interest.
Source: American Gastroenterological Association
In the excellent study by Peery and colleagues, statistics on health care utilization in the ambulatory and hospital settings, incidence and mortality from GI cancers, and mortality associated with other GI illnesses from 2007 to 2012 was collected using data from multiple complementary databases. This is the ideal methodology for this type of study because it quantifies utilization data from several complementary national databases. Of course, these data may be limited by systematic errors in ICD coding and costs are estimated using Medicare’s cost-to-charge ratio. Nevertheless, these data provide the best “snap shot” of trends in the burden of gastrointestinal and liver illness as of 2012.
What are the key points? First, the increase in the burden of GI and liver illness probably reflects the aging of the “baby boomer” population. Furthermore, since the Affordable Care Act is expanding access to health care, the burden on gastroenterologists is also likely to expand. Second, although we’re doing a good job with CRC screening, there is also room for improvement. While the incidence of CRC continues to decrease, only 58% of adults aged 50-75 years old had CRC screening in 2010. Third, HCV-associated hospitalizations have doubled from 2003 to 2012. Since HCV-associated cirrhosis is likely to increase until 2030, insurers and public health officials will have to carefully weigh the initial high cost of using new and highly effective regimens of direct-acting antiviral agents versus the downstream costs of managing these individuals after developing decompensated cirrhosis.
Dr. Philip S. Schoenfeld is professor of medicine and director, training program in GI epidemiology, division of gastroenterology, University of Michigan, Ann Arbor. He has no conflicts of interest.
In the excellent study by Peery and colleagues, statistics on health care utilization in the ambulatory and hospital settings, incidence and mortality from GI cancers, and mortality associated with other GI illnesses from 2007 to 2012 was collected using data from multiple complementary databases. This is the ideal methodology for this type of study because it quantifies utilization data from several complementary national databases. Of course, these data may be limited by systematic errors in ICD coding and costs are estimated using Medicare’s cost-to-charge ratio. Nevertheless, these data provide the best “snap shot” of trends in the burden of gastrointestinal and liver illness as of 2012.
What are the key points? First, the increase in the burden of GI and liver illness probably reflects the aging of the “baby boomer” population. Furthermore, since the Affordable Care Act is expanding access to health care, the burden on gastroenterologists is also likely to expand. Second, although we’re doing a good job with CRC screening, there is also room for improvement. While the incidence of CRC continues to decrease, only 58% of adults aged 50-75 years old had CRC screening in 2010. Third, HCV-associated hospitalizations have doubled from 2003 to 2012. Since HCV-associated cirrhosis is likely to increase until 2030, insurers and public health officials will have to carefully weigh the initial high cost of using new and highly effective regimens of direct-acting antiviral agents versus the downstream costs of managing these individuals after developing decompensated cirrhosis.
Dr. Philip S. Schoenfeld is professor of medicine and director, training program in GI epidemiology, division of gastroenterology, University of Michigan, Ann Arbor. He has no conflicts of interest.
In the excellent study by Peery and colleagues, statistics on health care utilization in the ambulatory and hospital settings, incidence and mortality from GI cancers, and mortality associated with other GI illnesses from 2007 to 2012 was collected using data from multiple complementary databases. This is the ideal methodology for this type of study because it quantifies utilization data from several complementary national databases. Of course, these data may be limited by systematic errors in ICD coding and costs are estimated using Medicare’s cost-to-charge ratio. Nevertheless, these data provide the best “snap shot” of trends in the burden of gastrointestinal and liver illness as of 2012.
What are the key points? First, the increase in the burden of GI and liver illness probably reflects the aging of the “baby boomer” population. Furthermore, since the Affordable Care Act is expanding access to health care, the burden on gastroenterologists is also likely to expand. Second, although we’re doing a good job with CRC screening, there is also room for improvement. While the incidence of CRC continues to decrease, only 58% of adults aged 50-75 years old had CRC screening in 2010. Third, HCV-associated hospitalizations have doubled from 2003 to 2012. Since HCV-associated cirrhosis is likely to increase until 2030, insurers and public health officials will have to carefully weigh the initial high cost of using new and highly effective regimens of direct-acting antiviral agents versus the downstream costs of managing these individuals after developing decompensated cirrhosis.
Dr. Philip S. Schoenfeld is professor of medicine and director, training program in GI epidemiology, division of gastroenterology, University of Michigan, Ann Arbor. He has no conflicts of interest.
Diseases such as Clostridium difficile infection, inflammatory bowel disease, and liver cancer continue to cost billions and cause many thousands of deaths in the United States every year, investigators reported in the December issue of Gastroenterology.
“Gastrointestinal and liver diseases are a source of substantial burden and cost,” said Dr. Anne Peery and her associates at the University of North Carolina School of Medicine and the Gillings School of Public Health, both in Chapel Hill. The Affordable Care Act has extended health insurance to more than 16 million Americans, which is “expected to change the landscape of care for GI illnesses” and intensifies the need for their comprehensive study, the researchers added.
They analyzed health care visits, costs, and deaths from GI, pancreatic, and hepatic diseases for 2007 through 2012 by using surveillance data from the Centers for Disease Control and Prevention, the Agency for Healthcare Research and Quality, and the National Cancer Institute. Chronic hepatitis C virus infection was a leading disease burden, they found. Associated emergency department visits rose by 176% between 2006 and 2012, hospital admissions increased by 225% between 2003 and 2012, and in-hospital mortality approached 6%. These trends reflect the aging of baby boomers, who make up three-quarters of infected patients, the investigators noted. As a result, rates of new liver cancers also are rising, and end-stage liver disease is expected to keep increasing until 2030, they added (Gastroenterology. 2015 Aug 20. doi: 10.1053/j.gastro.2015.08.045). Aging boomers are increasingly seeking care for other age-related GI disorders, the investigators reported. Outpatient visits for hemorrhoids are rising, as are emergency department visits for constipation and lower-GI bleeding, and hospitalizations for acute diverticulitis and C. difficile infection. Gastrointestinal hemorrhage was the most common diagnosis at hospitalization, accounting for more than 500,000 discharges and costing almost $5 billion dollars in 2012 alone, the researchers said.
Despite better treatments, hospital admissions for Crohn’s disease and ulcerative colitis also rose from less than 60,000 in 1993 to about 100,000 in 2012, said Dr. Peery and her associates. “This is congruent with earlier trends using the National Hospital Discharge Survey. Emergency department visits [for inflammatory bowel disease] are also rising,” they added.
In contrast, cases and deaths from colorectal cancer continue to drop, partly because of intensified screening efforts, the investigators said. They called the trend “encouraging,” but noted that CRC still tops cancers of the pancreas, liver, and intrahepatic bile ducts as the leading GI cause of mortality in the United States. In 2012, more than 51,000 Americans died from CRC, and screening efforts captured only 58% of those between 50 and 75 years old. Boosting that percentage to 80% by 2018 http://nccrt.org/tools/80-percent-by-2018/ could prevent 280,000 CRC cases and 200,000 deaths within 20 years, Dr. Peery and her associates noted.
The National Institutes of Health helped fund the work. The investigators reported having no conflicts of interest.
Source: American Gastroenterological Association
Diseases such as Clostridium difficile infection, inflammatory bowel disease, and liver cancer continue to cost billions and cause many thousands of deaths in the United States every year, investigators reported in the December issue of Gastroenterology.
“Gastrointestinal and liver diseases are a source of substantial burden and cost,” said Dr. Anne Peery and her associates at the University of North Carolina School of Medicine and the Gillings School of Public Health, both in Chapel Hill. The Affordable Care Act has extended health insurance to more than 16 million Americans, which is “expected to change the landscape of care for GI illnesses” and intensifies the need for their comprehensive study, the researchers added.
They analyzed health care visits, costs, and deaths from GI, pancreatic, and hepatic diseases for 2007 through 2012 by using surveillance data from the Centers for Disease Control and Prevention, the Agency for Healthcare Research and Quality, and the National Cancer Institute. Chronic hepatitis C virus infection was a leading disease burden, they found. Associated emergency department visits rose by 176% between 2006 and 2012, hospital admissions increased by 225% between 2003 and 2012, and in-hospital mortality approached 6%. These trends reflect the aging of baby boomers, who make up three-quarters of infected patients, the investigators noted. As a result, rates of new liver cancers also are rising, and end-stage liver disease is expected to keep increasing until 2030, they added (Gastroenterology. 2015 Aug 20. doi: 10.1053/j.gastro.2015.08.045). Aging boomers are increasingly seeking care for other age-related GI disorders, the investigators reported. Outpatient visits for hemorrhoids are rising, as are emergency department visits for constipation and lower-GI bleeding, and hospitalizations for acute diverticulitis and C. difficile infection. Gastrointestinal hemorrhage was the most common diagnosis at hospitalization, accounting for more than 500,000 discharges and costing almost $5 billion dollars in 2012 alone, the researchers said.
Despite better treatments, hospital admissions for Crohn’s disease and ulcerative colitis also rose from less than 60,000 in 1993 to about 100,000 in 2012, said Dr. Peery and her associates. “This is congruent with earlier trends using the National Hospital Discharge Survey. Emergency department visits [for inflammatory bowel disease] are also rising,” they added.
In contrast, cases and deaths from colorectal cancer continue to drop, partly because of intensified screening efforts, the investigators said. They called the trend “encouraging,” but noted that CRC still tops cancers of the pancreas, liver, and intrahepatic bile ducts as the leading GI cause of mortality in the United States. In 2012, more than 51,000 Americans died from CRC, and screening efforts captured only 58% of those between 50 and 75 years old. Boosting that percentage to 80% by 2018 http://nccrt.org/tools/80-percent-by-2018/ could prevent 280,000 CRC cases and 200,000 deaths within 20 years, Dr. Peery and her associates noted.
The National Institutes of Health helped fund the work. The investigators reported having no conflicts of interest.
Source: American Gastroenterological Association
FROM GASTROENTEROLOGY
Key clinical point: Gastrointestinal and liver diseases remain a major cause of health care utilization and associated costs in the United States.
Major finding: Hospital admissions and associated costs for Clostridium difficile infection, inflammatory bowel disease, and liver disease all rose substantially between 1993 and 2012.
Data source: Analysis of surveillance data from the Centers for Disease Control and Prevention, Agency for Healthcare Research and Quality, and National Cancer Institute.
Disclosures: The National Institutes of Health helped fund the work. The investigators reported having no conflicts of interest.
